Sofinnova Partners closed its Crossover II fund at €725 million, above target, to back Late-Stage European Life Sciences companies
Monday, November 16, 2026 · first reported by HedgeCo and 1 other
Sofinnova Partners closed Sofinnova Crossover II at €725 million ($815 million), above its original target. The fund will back about 15 late-stage European life sciences companies, with roughly 80% allocated to Europe.
- Fund
- Sofinnova Crossover II
- Size
- €725M (≈$815M)
- Stage
- Final close
- Asset class
- Private equity, Venture
- Geography
- Europe
In the data This close in the fund closes table · Every Sofinnova Partners close
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
2 sources- ASR Real Assets considers higher return target for €2.6bn farmland fundAgri Investor
- Diamondback nears $5bn acquisition of EnCap-backed Permian assetsPrivate Equity Wire
- HCMC Boosts venture Fund, 10 VIFC Members target $2.7 billionVietcetera
- Brookfield and KKR compete for $700m Gulf eyewear retailer EyewaPrivate Equity Wire
- Canaccord Genuity sells UK wealth arm to PE for £1.2bnInvestment Week
- Former Carlyle executive launches Asian secondaries firm targeting $50m dealsPrivate Equity Wire
Got news? Send it to us →